Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.

Related collections

Most cited references 18

Record: found
Abstract: not found
Article: not found

Vaccination of hematopoietic cell transplant recipients.

, J Englund, Christopher T. Small … (2009)

0 comments Cited 74 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Anthony L. Cunningham, Thomas C. Heineman, Himal Lal … (2018)

Abstract Background The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination. Clinical Trials Registration NCT01165177; NCT01165229.

0 comments Cited 70 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Nicolas Lecrenier, Pierre Beukelaers, Romulo E Colindres … (2018)

GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications. RZV showed >90% efficacy against HZ, sustained over 4 years of follow-up, in all studied age groups.

0 comments Cited 45 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date Created: July 09 2019

Publication date (Print): July 09 2019

Volume: 322

Issue: 2

Page: 123

Affiliations

[1 ]GlaxoSmithKline, Wavre, Belgium

[2 ]Hospital Universitario 12 de Octubre, Madrid, Spain

[3 ]GlaxoSmithKline, Rixensart, Belgium

[4 ]CureVac AG, Tübingen, Germany

[5 ]University Hospital of Montpellier, Montpellier, France

[6 ]Hospital Ramón y Cajal, Madrid, Spain

[7 ]Ege University Medical School, Izmir, Turkey

[8 ]Charles University Hospital, Prague, Czech Republic

[9 ]Rambam Health Care Campus, Haifa, Israel

[10 ]Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

[11 ]Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

[12 ]Chonnam National University Hwasun Hospital, Jellanamdo, Republic of Korea

[13 ]University of Kansas Cancer Center, Westwood

[14 ]Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, Spain

[15 ]Centro Integral Oncológico Clara Campal (CIOCC), Universidad CEU San Pablo, Madrid, Spain

[16 ]Weill Medical College of Cornell University, New York, New York

[17 ]Department of Hematology and Oncology, Charité University Medical Center, Berlin, Germany

[18 ]Preventive Medicine and Epidemiology Department, University Hospital Vall d’Hebron, Barcelona, Spain

[19 ]Haematology Department, Manchester University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, England

[20 ]Faculty of Biology, Medicine and Health, School of Medical Science, Division of Cancer Sciences, University of Manchester, Manchester, England

[21 ]Hospital de Donostia, San Sebastián, Spain

[22 ]Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea

[23 ]Hospital Ampang, Selangor, Malaysia

[24 ]Royal Hobart Hospital, Hobart, Australia

[25 ]Department of Clinical Haematology, Austin Health, Heidelberg, Australia

[26 ]Fred Hutchinson Cancer Research Center, Seattle, Washington

[27 ]Halozyme Therapeutics, San Diego, California

[28 ]University of Pennsylvania, Philadelphia

[29 ]Duke University Medical Center, Durham, North Carolina

Article

DOI: 10.1001/jama.2019.9053

PMC ID: 6618796

PubMed ID: 31287523

SO-VID: 9400621f-84d1-4b9c-aa15-56af2df28e63

History

Data availability:

Comments

Comment on this article

scite_

Cited by 57

See all cited by

Most referenced authors 779

See all reference authors

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation : A Randomized Clinical Trial

Read this article at

Abstract

Related collections

Stress signalling in stem cells

Most cited references 18

Vaccination of hematopoietic cell transplant recipients.

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 3,035

Cited by 57

Most referenced authors 779